{"schema_version":"secwatch.filing_event.v1","accession":"0001006837-25-000002","form_type":"8-K","ticker":"VATE","cik":"0001006837","company_name":"INNOVATE Corp.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.676044+00:00","generated_at":"2026-05-27T21:47:10.292068+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MediBeacon TGFR System Receives FDA Approval for Kidney Function Assessment","bullets":["FDA approved MediBeacon Transdermal GFR (tGFR) for assessing kidney function in adults with normal or impaired renal function without input of age, sex, race.","TGFR uses a non-radioactive fluorescent agent (Lumitrace) with a transdermal sensor; no blood draws or urine analysis needed.","Primary efficacy endpoint met: P30 value of 94% (95% CI: 89.4%-96.9%) in clinical study across GFR ranges and skin tones.","More than 800 million people globally have chronic kidney disease; TGFR aims to improve point-of-care assessment."],"urls":{"canonical":"https://secwatch.observer/filing/0001006837-25-000002","json":"https://secwatch.observer/filing/0001006837-25-000002.json","markdown":"https://secwatch.observer/filing/0001006837-25-000002.md","text":"https://secwatch.observer/filing/0001006837-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006837/000100683725000002/0001006837-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006837/000100683725000002/hchc-20250117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T21:47:10.292068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}